Drägerwerk reports lower Q3 EBIT: Drägerwerk stock gains 2.59 percent

Published on 10/21/2026 at 10:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 EBIT fell to EUR 48 million on October 14, 2026. Drägerwerk stock costs EUR 96.95, 2.59 percent above Xetra close of EUR 94.50.

Profit pressure meets stronger orders

Drägerwerk reported EUR 48 million EBIT for the third quarter of 2026 on October 14, 2026.
The company kept its 2026 forecast of 2.0 to 6.0 percent revenue growth and a 6.0 to 8.0 percent EBIT margin.
Drägerwerk stock trades at EUR 96.95 at 10:18 a.m. CEST at Lang & Schwarz on October 21, 2026, 2.59 percent above the Xetra close of October 20, 2026.
The quarterly statement is scheduled for October 29, 2026.

Frankfurter Börsen-Handelsraum mit digitalen Kursanzeigen für den Medizintechnik-Sektor — Drägerwerk AG & Co. KGaA Frankfurter Börse Handelsraum Medizintechnik Sektor Kursanzeigen Händler DE0005550636, Illustration mit AI erstellt.

Drägerwerk (ISIN DE0005550636) reported third-quarter 2026 EBIT of EUR 48 million on October 14, 2026, down from EUR 56.7 million in the prior-year quarter despite EUR 20.1 million in customs duty refunds. The company kept its 2026 forecast, while Drägerwerk stock gains 2.59 percent above the Xetra close. The market is weighing stronger orders against weaker quarterly profitability.

Why did quarterly profit weaken?

According to Deutsche Boerse, third-quarter revenue rose 2.1 percent year over year to EUR 851 million, but the EBIT margin fell to 5.6 percent from 6.8 percent. The refund helped reported earnings, yet higher functional expenses outweighed the modest revenue increase.

The order picture was more constructive. Order intake rose 8.2 percent year over year to EUR 926 million, with the safety division contributing a 20.2 percent increase to EUR 452 million. Medical order intake declined 3.0 percent to EUR 474 million, creating a clear split between the two businesses.

Three dates show the changing picture

On July 30, 2026, Drägerwerk reported first-half revenue growth of 7.7 percent and an EBIT margin of 4.0 percent, according to Stock Analysis. On August 31, 2026, mwb research lifted its Drägerwerk price target to EUR 130.00, according to ResearchHub. On October 14, 2026, Drägerwerk released the preliminary third-quarter figures and confirmed its forecast.

What must improve for the forecast?

Drägerwerk still targets currency-adjusted revenue growth of 2.0 to 6.0 percent and an EBIT margin of 6.0 to 8.0 percent for 2026. After nine months, revenue stood at EUR 2,454 million and EBIT at EUR 112 million, including EUR 27.9 million of refunded customs duties. The gap between the nine-month margin of 4.6 percent and the annual target range makes the final quarter especially important.

The next reporting date is set

The company will publish its third-quarter statement on October 29, 2026, according to Deutsche Boerse. That release should provide the detailed segment figures behind the preliminary margin development.

Stock trades above the Xetra close

Drägerwerk stock was trading at EUR 96.95 at Lang & Schwarz on October 21, 2026, at 10:18 a.m. CEST, 2.59 percent above the Xetra close of October 20, 2026 at EUR 94.50. The company has a market capitalization of EUR 1.8 billion and a 52-week range of EUR 66.00 to EUR 125.40 as of October 21, 2026. The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.